Organization (Industry)
HOLLISTER INCORPORATED
ClinicalTrials.gov lists HOLLISTER INCORPORATED as lead sponsor of 16 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers HOLLISTER INCORPORATED: 16 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (9)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Urinary Retention | 3 |
| Respiratory Insufficiency | 2 |
| Urinary Bladder, Neurogenic | 2 |
| Urinary Incontinence | 2 |
| Dermatitis, Contact | 1 |
Showing 5 of 9 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 1 of 2 on time (n=2) |
Journals published in (11)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society | 2 |
| Anesthesia and analgesia | 1 |
| BMC urology | 1 |
| BMJ open | 1 |
| International urology and nephrology | 1 |
Showing 5 of 11 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 470 | 148 | 2025-12-23 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 10 |
FDA recalls (5)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| AnchorFast Guard Select, Oral Endotracheal Tube Fastener, REF 9700, | Class II | 2024-12-23 |
| AnchorFast SlimFit, Oral Endotracheal Tube Fastener, REF 9787, | Class II | 2024-12-23 |
| AnchorFast, Oral Endotracheal Tube Fastener, REF 9799, | Class II | 2024-12-23 |
| AnchorFast Guard, Oral Endotracheal Tube Fastener, REF 9800, | Class II | 2024-12-23 |
| Vertical Drain Tube Attachment Device (VTAD) (Gastrointestinal tube and accessories) - Product Usage: designed to stabilize and secure a variety of catheters, surgical drains, and tubes from sizes 5-40 French. | Class II | 2021-02-11 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 5 | 2025-07-16 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| HOLLISTER INCORPORATED | LIBERTYVILLE, US | FDA | |
| HOLLISTER, INC. | Mount Juliet, US | FDA | |
| HOLLISTER INCORPORATED | STUARTS DRAFT, US | FDA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Parexel | Uses vendor | 1 |
Latest dated events (506)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 506 events.
Biomarker capability evidence (5)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| MCF2L | Trial sponsor | Named in trial inclusion criteria |
| OS9 | Trial sponsor | Named in trial inclusion criteria |
| MCF2L | Trial sponsor | Exploratory endpoint in a trial |
| MCF2L | Trial sponsor | Mentioned in trial text |
| OS9 | Trial sponsor | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.